Crescendo will participate in the upcoming investor conference

[ad_1]

Crescendo Biologics Ltd (Crescendo), a clinical-stage immuno-oncology company that develops new targeted T cell enhancement therapies, announced today that senior members of the executive team will participate in the following three meetings to meet with investors to discuss the company’s business strategy and technology , Discovery platform and development plan.

  • Kempen Life Science Cross Conference (virtual), June 16, 2021
  • JMP Securities Life Science Conference (virtual), June 17, 2021

    Demonstration time is 10:00 AM Eastern Time, 3:00 PM British Summer Time

  • BioTrinity (Virtual & London, UK), June 21, 2021

    Speech at 2:20 pm British Summer Time

If you are interested in meeting the team at these events, please contact the company via email Investor@crescendobiologics.com.

For more information and updated schedules, please refer to the respective conference websites.

-Finish-

About Crescendo Biologics

Crescendo Biologics is a private clinical-stage immuno-oncology company that develops new, targeted T cell-enhanced Humabody® therapies.

Crescendo Biologics leads its proprietary pipeline and develops CB307, a new type of CD137 x PSMA Humabody® with extended half-life for the selective activation of tumor-specific T cells in the tumor microenvironment. CB307 aims to achieve a longer-lasting anti-cancer effect while avoiding systemic toxicity, and the clinical plan of CB307 is underway in patients with PSMA-positive solid tumors.

The company’s ability to develop multifunctional Humabody® therapies is based on its unique, patent-protected transgenic mouse platform that can generate 100% human VH domain building blocks (Humabody® VH). These powerful molecules can be configured to engage therapeutic targets in such a way, thereby providing new biology and superior biodistribution. This results in a larger therapeutic window compared to traditional IgG methods. The format based on Humabody® can also be applied to a range of non-cancer indications.

In addition to Crescendo’s proprietary pipeline, the company also has a global multi-target discovery and development collaboration with Takeda; a clinical development partnership with Cancer Research UK; and an exclusive global licensing agreement with Zai Lab, and its product candidates are in progress Phase 1 clinical trial.

Crescendo Biologics is located in Cambridge, UK and is supported by blue chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit www.crescendobiologics.com And follow @HUMABODY.



[ad_2]

Source link

Recommended For You

About the Author: News Center